Trial Profile
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of Clofazimine (CFZ) in Cryptosporidiosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Clofazimine (Primary)
- Indications Cryptosporidiosis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms CRYPTOFAZ
- 24 Mar 2023 Results (n=23) to characterize the population pharmacokinetics (PK) of oral clofazimine and identify significant covariates on clofazimine PK, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 11 Apr 2020 Results published in the Clinical Infectious Diseases
- 11 Aug 2019 Status changed from recruiting to discontinued.